BeOne Medicines AG (HKG:6160)
183.50
+1.60 (0.88%)
Jul 10, 2026, 4:08 PM HKT
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.51B USD in the quarter ending March 31, 2026, with 35.46% growth. This brings the company's revenue in the last twelve months to $5.67B, up 36.75% year-over-year. In the year 2025, BeOne Medicines AG had annual revenue of $5.34B with 40.23% growth.
Revenue (ttm)
$5.67B
Revenue Growth
+36.75%
P/S Ratio
5.79
Revenue / Employee
$472.84K
Employees
12,000
Market Cap
260.35B HKD
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
| Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
| Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 35.43B |
| WuXi Biologics | 24.25B |
| 3SBio | 19.69B |
| Innovent Biologics | 14.51B |
| Genscript Biotech | 7.47B |
| Shanghai Henlius Biotech | 7.42B |
| RemeGen | 3.84B |
| Akeso | 3.40B |
BeOne Medicines AG News
- 1 day ago - BeOne Medicines (ONC) Receives FDA Orphan Designation for Pancreatic Cancer Treatment - GuruFocus
- 1 day ago - BeOne Medicines treatment of pancreatic cancer granted orphan status - TheFly
- 4 days ago - BeOne Medicines price target raised to $416 from $413 at Truist - TheFly
- 4 days ago - BeOne Medicines price target raised to $451 from $436 at RBC Capital - TheFly
- 11 days ago - BeOne Medicines (ONC) Reports Positive Phase 3 MANGROVE Study Results - GuruFocus
- 11 days ago - BeOne Medicines’ Brukinsa shows efficacy in Phase 3 lymphoma trial - TheFly
- 11 days ago - BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma - Business Wire
- 21 days ago - Baker Bros. Advisors LP's Strategic Acquisition of BeOne Medicines Ltd Shares - GuruFocus